- Home
- RFIL vs ALXO Comparison
RFIL vs ALXO Comparison
Compare RFIL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RFIL | ALXO |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.3M | 205.9M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RFIL | ALXO |
|---|---|---|
| Price | $10.07 | $2.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $11.25 | $3.50 |
| AVG Volume (30 Days) | 176.4K | ★ 1.0M |
| Earning Date | 06-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | 26.36 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $55,325,000.00 | N/A |
| Revenue This Year | $9.65 | N/A |
| Revenue Next Year | $6.40 | N/A |
| P/E Ratio | $143.71 | ★ N/A |
| Revenue Growth | ★ 10.22 | N/A |
| 52 Week Low | $5.54 | $1.02 |
| 52 Week High | $22.30 | $2.66 |
Technical Indicators
Market Signals| Indicator | RFIL | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 30.60 | 52.18 |
| Support Level | $9.57 | $2.01 |
| Resistance Level | $13.59 | $2.17 |
| Average True Range (ATR) | 0.57 | 0.10 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 2.38 | 58.33 |
Price Performance
Historical ComparisonAbout RFIL RF Industries Ltd.
RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.